{
  "docId": "019de075-e1f8-726f-9315-81fdfad7abab",
  "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 37,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to present distinct technological approaches.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/6",
  "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab",
  "deckJsonHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab.json",
  "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.11,
        "y": 0.245
      },
      "kind": "list",
      "text": "BEST-IN-CLASS ANTIBODY ENGINEERING",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "350f95ce-2975-42b5-a2b1-7363806f757d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.68,
        "y": 0.245
      },
      "kind": "list",
      "text": "PRECISION IMMUNOLOGY APPROACHES",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "525bc4e4-490f-419a-a79f-d919007e9553",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.41,
        "y": 0.245
      },
      "kind": "list",
      "text": "RATIONAL THERAPEUTIC COMBINATIONS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b226cafc-6be5-4d38-9452-28d13f388015",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.23,
        "x": 0.66,
        "y": 0.618
      },
      "kind": "paragraph",
      "text": "GENETIC AND BIOMARKER SELECTION TO IDENTIFY MOST LIKELY RESPONDERS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07de5a3b-dba3-4964-a684-d0b60ce91b60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.23,
        "x": 0.11,
        "y": 0.618
      },
      "kind": "paragraph",
      "text": "HALF-LIFE EXTENSION TECHNOLOGIES TO IMPROVE CONVENIENCE",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79fc8c67-6fbb-4e71-ba39-e2070b9e4f1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.23,
        "x": 0.39,
        "y": 0.618
      },
      "kind": "paragraph",
      "text": "COMBINATION TARGETING TO ENHANCE REMISSION RATES",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d2fa78f-3115-49f9-816c-29acf142d359",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.96,
        "x": 0.02,
        "y": 0.845
      },
      "kind": "source-note",
      "text": "Sources: 1 Several half-life extended antibodies are in clinical development... 2 JNJ VEGA Phase 2 study... 3 Prometheus Biosciences demonstrated a ~13% increase in clinical remission rates in CDx+ patients...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "435ee358-c276-4a8e-ba2d-b0cc8162eee0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Our strategy is built on three validated approaches to address unmet needs in IBD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e058fc06-b38e-4c1c-86a8-44181eeb6ba0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b7091b28-a531-4677-b268-c8e3a5804fd9",
      "evidence": "The problem statement on page 5 sets up the need for improved treatment",
      "position": 0,
      "objective": "What are the consequences of not improving IBD treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 19,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563",
      "evidence": "The solution section presents a clear 'why' for Spyre's approach",
      "position": 1,
      "objective": "Why does Spyre's approach make sense?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}